Athira pharma highlights therapeutic potential of fosgonimeton in presentation of additional biomarker data in mild-to-moderate alzheimer's disease patients from act-ad phase 2 study at ctad conference

Fosgonimeton treatment-related reductions in biomarkers of neurodegeneration (nfl) and neuroinflammation (gfap) significantly correlated with improvements in clinical outcomes as assessed by the gst, a composite score of cognition (adas-cog11) and function (adcs-adl23)
ATHA Ratings Summary
ATHA Quant Ranking